SLC5A2 and diabetic kidney disease: The shift in perspective towards phytomedicinal therapies that mimic SGLT2 inhibitors, while also improving complications like diabetic nephropathy [55], can be explained by positive translational and clinical studies thus far that present effective and relatively safe treatment in comparison to synthetic cannabinoid therapeutics.